Aurobindo gets FDA ok for didanosine
This article was originally published in Scrip
Executive Summary
Aurobindo Pharmahas received final approval from the US FDA to manufacture and market didanosine delayed-release (enteric-coated) capsules 125mg, 200mg, 250mg and 400mg, generic versions of Bristol-Myer Squibb's HIV treatment Videx EC delayed-release capsules. It represents Aurobindo's 78th ANDA approval from the FDA.